Trinity Biotech Uni-Gold Recombigen
This article was originally published in The Gray Sheet
Executive Summary
HIV-1 antibody test gains a CLIA waiver for use with venous whole blood samples, expanding its market potential to about 180,000 hospitals, physician offices and clinics. The 10-minute test received PMA approval in December 2003 for use with serum, plasma and whole blood. A finger-stick whole blood claim is pending at FDA (1"The Gray Sheet" Jan. 5, 2004, p. 6)...
You may also be interested in...
Trinity Triumvirate: Uni-Gold First Rapid HIV Test Cleared For 3 Sample Types
Trinity Biotech plans shortly to file a PMA supplement application for its Uni-Gold Recombigen HIV test to detect antibodies to HIV in fingerstick blood
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.